{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:03:53Z","timestamp":1778011433568,"version":"3.51.4"},"reference-count":26,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiatives 2 Joint Undertaking","award":["116106"],"award-info":[{"award-number":["116106"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Bleomycin is an oncolytic and antibiotic agent used to treat various human cancers because of its antitumor activity. Unfortunately, up to 46% of the patients treated with bleomycin develop drug-induced interstitial lung disease (DIILD) and potentially life-threatening interstitial pulmonary fibrosis. Tools and biomarkers for predicting and detecting DIILD are limited. Therefore, we aimed to evaluate the feasibility of 18F-FDG PET\/CT, PET radiomics, and machine learning in distinguishing DIILD in an explorative pilot study. Methods: Eighteen Hodgkin\u2019s lymphoma (HL) patients, of whom 10 developed DIILD after treatment with bleomycin, were retrospectively included. Five diffuse large B-cell lymphoma (DLBCL) patients were included as a control group since they were not treated with bleomycin. All patients underwent 18F-FDG PET\/CT scans before (baseline) and during treatment (interim). Structural changes were assessed by changes in Hounsfield Units (HUs). The 18F-FDG PET scans were used to assess metabolic changes by examining the feasibility of 504 radiomics features, including the mean activity of the lungs (SUVmean). A Random Forest (RF) classifier evaluated the identification and prediction of DIILD based on PET radiomics features. Results: HL patients who developed DIILD showed a significant increase in standard SUV metrics (SUVmean; p = 0.012, median increase 37.4%), and in some regional PET radiomics features (texture strength; p = 0.009, median increase 101.6% and zone distance entropy; p = 0.019, median increase 18.5%), while this was not found in HL patients who did not develop DIILD and DLBCL patients. The RF classifier correctly identified DIILD in 72.2% of the patients and predicted the development of DIILD correctly in 50% of the patients. There were no significant differences in HUs over time within all three patient groups. Conclusions: Our explorative longitudinal pilot study suggests that certain regional 18F-FDG PET radiomics features can effectively identify DIILD in HL patients treated with bleomycin, as significant longitudinal increases were observed in SUVmean, texture strength, and zone distance entropy after the development of DIILD. The metabolic activity of these features did not significantly increase over time in DLBCL patients and HL patients who did not develop DIILD. This indicates that 18F-FDG PET radiomics, with and without machine learning, might serve as potential biomarkers for detecting DIILD.<\/jats:p>","DOI":"10.3390\/diagnostics14222531","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:36:51Z","timestamp":1731404211000},"page":"2531","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of Using 18F-FDG PET\/CT Radiomics and Machine Learning to Detect Drug-Induced Interstitial Lung Disease"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8558-4872","authenticated-orcid":false,"given":"Charlotte L. C.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9571-9362","authenticated-orcid":false,"given":"Gerben J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8121","authenticated-orcid":false,"given":"Sanne E.","family":"Wiegers","sequence":"additional","affiliation":[{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne W. S.","family":"Jauw","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-5922","authenticated-orcid":false,"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"ref_1","first-page":"200","article-title":"New antibiotics, bleomycin A and B","volume":"19","author":"Umezawa","year":"1966","journal-title":"J. Antibiot."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-77-6-861","article-title":"Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients","volume":"77","author":"Yagoda","year":"1972","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14740338.2.6.587","article-title":"Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer","volume":"2","author":"Kawai","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: Who are the patients with increased risk?","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02034932","article-title":"Mechanisms of bleomycin-induced lung damage","volume":"65","author":"Hay","year":"1991","journal-title":"Arch. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chianese, M., Screm, G., Salton, F., Confalonieri, P., Trotta, L., Barbieri, M., Ruggero, L., Mari, M., Reccardini, N., and Geri, P. (2024). Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows. Pharmaceuticals, 17.","DOI":"10.3390\/ph17060709"},{"key":"ref_7","first-page":"e54268","article-title":"A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review","volume":"16","author":"Man","year":"2024","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0009-9260(05)80161-8","article-title":"High-resolution computed tomography of drug-induced lung disease","volume":"46","author":"Padley","year":"1992","journal-title":"Clin. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.3324\/haematol.11856","article-title":"FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin\u2019s disease\u2014A useful tool for monitoring pulmonary toxicity and disease activity","volume":"92","author":"Buchler","year":"2007","journal-title":"Haematologica"},{"key":"ref_11","first-page":"010388","article-title":"Lungs on fire","volume":"2013","author":"Batra","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12149-007-0109-9","article-title":"FDG positron emission tomography imaging of drug-induced pneumonitis","volume":"22","author":"Morikawa","year":"2008","journal-title":"Ann. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/0972-3919.202242","article-title":"FDG PET-CT: Need for Vigilance in Patients Treated with Bleomycin","volume":"32","author":"Paschali","year":"2017","journal-title":"Indian J. Nucl. Med."},{"key":"ref_14","first-page":"320","article-title":"Increased pulmonary FDG uptake in bleomycin-associated pneumonitis","volume":"30","author":"Klaeser","year":"2007","journal-title":"Onkologie"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Exarchos, K.P., Gkrepi, G., Kostikas, K., and Gogali, A. (2023). Recent Advances of Artificial Intelligence Applications in Interstitial Lung Diseases. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132303"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000502374","article-title":"Can we predict bleomycin toxicity with PET-CT?","volume":"142","author":"Comert","year":"2019","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: Extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-023-00799-2","article-title":"Quantitative PET-based biomarkers in lymphoma: Getting ready for primetime","volume":"20","author":"Alderuccio","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Toyama, Y., Hotta, M., Motoi, F., Takanami, K., Minamimoto, R., and Takase, K. (2020). Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-73237-3"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.03418","article-title":"Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)","volume":"38","author":"Lugtenburg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","first-page":"1753","article-title":"Quantitative oncology molecular analysis suite: ACCURATE","volume":"59","author":"Boellaard","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pfaehler, E., Zwanenburg, A., de Jong, J.R., and Boellaard, R. (2019). RaCaT: An open source and easy to use radiomics calculator tool. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212223"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1057\/jt.2009.5","article-title":"The correlation coefficient: Its values range between +1\/\u22121, or do they?","volume":"17","author":"Ratner","year":"2009","journal-title":"J. Target. Meas. Anal. Mark."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ypsilantis, P.P., Siddique, M., Sohn, H.M., Davies, A., Cook, G., Goh, V., and Montana, G. (2015). Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137036"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/22\/2531\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:30:52Z","timestamp":1760113852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/22\/2531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":26,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["diagnostics14222531"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14222531","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}